Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GHDX [NASD]
Genomic Health Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own1.60% Shs Outstand31.18M Perf Week-2.37%
Market Cap834.38M Forward P/E- EPS next Y-0.34 Insider Trans6.63% Shs Float29.22M Perf Month-1.44%
Income-12.80M PEG- EPS next Q-0.18 Inst Own90.10% Short Float7.28% Perf Quarter-18.91%
Sales261.60M P/S3.19 EPS this Y-261.50% Inst Trans-0.13% Short Ratio9.18 Perf Half Y-9.75%
Book/sh4.69 P/B5.71 EPS next Y60.00% ROA-8.10% Target Price31.58 Perf Year-11.13%
Cash/sh3.38 P/C7.92 EPS next 5Y- ROE-9.80% 52W Range25.50 - 38.99 Perf YTD-8.58%
Dividend- P/FCF- EPS past 5Y5.90% ROI-8.80% 52W High-31.37% Beta0.47
Dividend %- Quick Ratio4.90 Sales past 5Y18.80% Gross Margin83.90% 52W Low4.94% ATR1.31
Employees684 Current Ratio4.90 Sales Q/Q13.90% Oper. Margin-4.50% RSI (14)46.63 Volatility4.55% 4.57%
OptionableYes Debt/Eq0.00 EPS Q/Q-600.00% Profit Margin-5.20% Rel Volume0.61 Prev Close28.04
ShortableYes LT Debt/Eq0.00 EarningsApr 28 Payout- Avg Volume231.80K Price26.76
Recom2.70 SMA20-0.45% SMA50-2.62% SMA200-13.60% Volume142,192 Change-4.56%
02-Aug-13Reiterated MLV & Co Hold $30 → $35
21-Feb-12Downgrade GARP Research Buy → Neutral
08-Feb-12Downgrade MLV & Co Buy → Hold $31.50 → $30
12-Dec-11Reiterated Ladenburg Thalmann Buy $26 → $32
02-Nov-11Upgrade Ladenburg Thalmann Neutral → Buy $26
11-Oct-11Reiterated RBC Capital Mkts Sector Perform $27 → $21
05-Oct-11Initiated Oppenheimer Perform $20
09-Feb-11Downgrade Ladenburg Thalmann Buy → Neutral
16-Nov-10Initiated Canaccord Genuity Hold $19
21-Apr-10Initiated RBC Capital Mkts Sector Perform
14-Apr-10Initiated William Blair Mkt Perform
22-Jan-10Upgrade Piper Jaffray Neutral → Overweight
21-Jan-10Initiated Jefferies & Co Hold $18
08-Jan-10Initiated ThinkEquity Buy
11-Jun-09Upgrade Thomas Weisel Market Weight → Overweight $23
08-Oct-08Initiated Oppenheimer Perform
08-Sep-08Downgrade Canaccord Adams Buy → Hold $24 → $22
06-Aug-08Reiterated JMP Securities Mkt Outperform $32 → $35
07-May-08Reiterated RBC Capital Mkts Outperform $27 → $26
07-May-08Reiterated Canaccord Adams Buy $22 → $24
22-Apr-14 08:00AM  Global Adoption of Oncotype DX® Breast Cancer Test Continues to Grow with Achievement of Two Significant International Milestones PR Newswire
08:00AM  British Columbia Breast Cancer Patients Gain Access to Oncotype DX® To Help Guide Chemotherapy Treatment Decisions CNW Group
08-Apr-14 02:20PM  Balanced View on Genomic Health Zacks
03-Apr-14 08:13AM  Vipshop Holdings, Genomic Health, Toyota, Honda and Kyocera highlighted as Zacks Bull and Bear of the Day Zacks
01:00AM  Bear of the Day: Genomic Health (GHDX) Zacks
31-Mar-14 04:11PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
20-Mar-14 05:15PM  Genomic Health Unveils Oncotype DX Data Zacks
19-Mar-14 08:00AM  Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe PR Newswire
18-Mar-14 04:32PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
15-Mar-14 01:04PM  GENOMIC HEALTH INC Financials EDGAR Online Financials
11-Mar-14 04:42PM  GENOMIC HEALTH INC Files SEC form 10-K, Annual Report EDGAR Online
27-Feb-14 07:49AM  Zacks Rank #5 Additions for Thursday Zacks
13-Feb-14 06:38AM  What Makes Genomic Health (GHDX) a Strong Sell? Zacks
11-Feb-14 11:24AM  Commit To Buy Genomic Health At $22.50, Earn 8.4% Annualized Using Options at TheStreet
11:24AM  Commit To Buy Genomic Health At $22.50, Earn 8.4% Annualized Using Options
07-Feb-14 06:20AM  Genomic Health downgraded to Neutral from Outperform at Credit Suisse at theflyonthewall.com
06:20AM  Genomic Health downgraded to Neutral from Outperform at Credit Suisse
06-Feb-14 06:34AM  Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0% Zacks
06:34AM  Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0%
05-Feb-14 11:40AM  Myriad Genetics rallies after buying rival, increasing 2014 outlook at theflyonthewall.com -8.95%
11:40AM  Myriad Genetics rallies after buying rival, increasing 2014 outlook
09:30AM  Q4 Loss Narrower Than Expected at Genomic, Revs Up Y/Y Zacks
09:30AM  Q4 Loss Narrower Than Expected at Genomic, Revs Up Y/Y
04-Feb-14 08:10PM  Genomic Health Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
08:10PM  Genomic Health Management Discusses Q4 2013 Results - Earnings Call Transcript
04:09PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:01PM  Genomic Health Announces Year-End 2013 Financial Results, Provides 2014 Financial Outlook PR Newswire
07:07AM  Q4 2013 GENOMIC HEALTH INC Earnings Release - After Market Close CCBN
29-Jan-14 08:00AM  Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium PR Newswire
08:00AM  Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium
28-Jan-14 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on Tuesday, February 4, 2014 PR Newswire
08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on Tuesday, February 4, 2014
15-Jan-14 03:58PM  Illumina's New Low-Cost Genome Machine Will Change Health Care Forever at BusinessWeek
03:58PM  Illumina's New Low-Cost Genome Machine Will Change Health Care Forever
07-Jan-14 08:00AM  Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients PR Newswire
08:00AM  Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
06:50AM  GTX Inc. (GTXI) Worth Watching: Stock Rises 7.2% Zacks
06:50AM  GTX Inc. (GTXI) Worth Watching: Stock Rises 7.2%
06:45AM  Exelixis (EXEL) Jumps: Stock Moves 11.1% Higher Zacks
06:45AM  Exelixis (EXEL) Jumps: Stock Moves 11.1% Higher
06-Jan-14 04:00PM  Genomic Health Announces Presentation at J.P. Morgan Healthcare Conference PR Newswire
04:00PM  Genomic Health Announces Presentation at J.P. Morgan Healthcare Conference
27-Dec-13 01:55PM  Genomic Health Remains Neutral Zacks
01:55PM  Genomic Health Remains Neutral
24-Dec-13 06:10AM  Synthetic Biologics (SYN) in Focus: Stock Surges 18.1% Zacks
06:10AM  Synthetic Biologics (SYN) in Focus: Stock Surges 18.1%
14-Dec-13 08:35AM  Genomic Health Announces Presentation of New Oncotype DX® Studies Underscoring Unique Value of the Test in Early-Stage Breast Cancer at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium PR Newswire
08:35AM  Genomic Health Announces Presentation of New Oncotype DX® Studies Underscoring Unique Value of the Test in Early-Stage Breast Cancer at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium
10-Dec-13 04:31PM  Genomic Health Breaks Below 200-Day Moving Average - Notable for GHDX at Forbes
04:31PM  Genomic Health Breaks Below 200-Day Moving Average - Notable for GHDX
03:15PM  Why Genomic Health Is A Solid Long-Term Buy at Seeking Alpha
03:15PM  Why Genomic Health Is A Solid Long-Term Buy
07-Dec-13 09:08AM  How 23andMe Can Spur Growth for These Diagnostics Companies at Motley Fool
09:08AM  How 23andMe Can Spur Growth for These Diagnostics Companies
04-Dec-13 08:00AM  Genomic Health Announces Presentation of Oncotype DX® Studies at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) PR Newswire
08:00AM  Genomic Health Announces Presentation of Oncotype DX® Studies at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) PR Newswire
26-Nov-13 03:35PM  GHDX Partners Almac for Cancer Test Zacks
06:01AM  GENOMIC HEALTH INC Files SEC form 8-K, Other Events EDGAR Online
25-Nov-13 04:01PM  InPlay: Genomic Health and Almac Group enter exclusive in-licensing agreement to develop and commercialize anthracycline chemotherapy benefit test for high risk breast cancer Briefing.com
04:01PM  Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer PR Newswire
22-Nov-13 08:02AM  InPlay: Genomic Health announces publication of Oncotype DX study Briefing.com
08:00AM  Genomic Health Announces Publication of Oncotype DX® Prostate Cancer Test Analytical Validation Study PR Newswire
14-Nov-13 03:10PM  Positive Results for Genomic's Colon Cancer Test Zacks
01:04PM  GENOMIC HEALTH INC Financials EDGAR Online Financials
13-Nov-13 08:07AM  Genomic Health's Oncotype DX colon cancer test validated in publication at theflyonthewall.com
08:04AM  InPlay: Genomic Health announces colon cancer publication in journal of clinical oncology supporting wider oncotype DX utilization Briefing.com
08:00AM  Genomic Health Announces Colon Cancer Publication in Journal of Clinical Oncology Supporting Wider Oncotype DX® Utilization PR Newswire
08-Nov-13 12:40PM  Genomic Health Tops Q3 Earnings Ests Zacks +5.30%
07-Nov-13 04:11PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
06-Nov-13 08:04PM  Why OpenTable, Organovo Holdings, and Genomic Health Soared Today at Motley Fool +11.37%
12:38PM  Why Genomic Health Inc. Shares Spiked Higher at Motley Fool
06:39AM  Is Genomic Health, Inc. (GHDX) Ready to Breakout? Zacks
05-Nov-13 04:23PM  InPlay: Genomic Health beats by $0.06, beats on revs Briefing.com
04:08PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principa EDGAR Online
04:01PM  Genomic Health Announces Third Quarter 2013 Financial Results and Business Progress PR Newswire
08:01AM  InPlay: Genomic Health announces colon cancer publication supporting wider Oncotype DX utilization Briefing.com
08:01AM  Genomic Health Announces Colon Cancer Publication Supporting Wider Oncotype DX® Utilization PR Newswire
07:07AM  Q3 2013 GENOMIC HEALTH INC Earnings Release - After Market Close CCBN
29-Oct-13 08:00AM  Genomic Health to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013 PR Newswire
24-Oct-13 12:18PM  Organovo's 3 Biggest Opportunities in 3-D Bioprinting at Motley Fool
07-Oct-13 02:42PM  Genomic Health Has Sickly Stock Chart at Forbes
04-Oct-13 09:47AM  Bear Of The Day: Genomic Health at Seeking Alpha
03-Oct-13 07:23AM  WageWorks, Genomic Health, Barrick Gold, Newmont and AngloGold Ashanti highlighted as Zacks Bull and Bear of the Day Zacks
12:55AM  Bear of the Day: Genomic Health (GHDX) Zacks
01-Oct-13 06:17AM  Genomic Health presents Oncotype DX studies reinforcing value of tests theflyonthewall.com
05:26AM  InPlay: Genomic Health presents Oncotype DX studies reinforcing value of tests in guiding treatment for multiple cancers Briefing.com
05:00AM  Genomic Health Announces Presentation of Oncotype DX® Studies Reinforcing Value of Tests in Guiding Treatment for Multiple Cancers PR Newswire
26-Sep-13 06:06PM  Medicare's Greatest Enemy Won't Be Defunded at Motley Fool
25-Sep-13 06:46AM  InPlay: Genomic Health: NICE recommends co's Oncotype DX Test to guide chemotherapy treatment decisions for qualified early-stage invasive breast cancer patients Briefing.com
05:46AM  InPlay: Genomic Health: NICE recommends co's Oncotype DX Test to guide chemotherapy treatment decisions for qualified early-stage invasive breast cancer patients Briefing.com
05:30AM  NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer Patients PR Newswire
20-Sep-13 06:01AM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
27-Aug-13 01:29PM  Genomic Health: Market Leader In Cancer Predictions at Seeking Alpha
23-Aug-13 03:34PM  Is Myriad Innovative Enough To Survive The Competition? at Seeking Alpha
22-Aug-13 08:06AM  InPlay: Genomic Health: Updated St. Gallen International Breast Cancer guidelines, for the second time, recognize Oncotype DX as the only validated multi-gene test able to predict chemotherapy benefit Briefing.com
08:00AM  Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to Predict Chemotherapy Benefit PR Newswire
21-Aug-13 02:10PM  Interview with William Quirk, Piper Jaffray & Co. Managing Director and Senior Research Analyst: Solid Fundamentals for Diagnostics and Life Science Tools Despite Short-Term Challenges Wall Street Transcript
16-Aug-13 12:52PM  Richard King, the Director, President and CEO of AcelRx Pharmaceuticals, Inc. (ACRX), Interviews with The Wall Street Transcript Wall Street Transcript
15-Aug-13 01:04PM  GENOMIC HEALTH INC Financials EDGAR Online Financials
07-Aug-13 05:00PM  Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth Conference PR Newswire
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, facilitating physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as is used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shak StevenEVP of R&DApr 14Option Exercise2.887,00020,160318,547Apr 16 04:19 PM
Shak StevenEVP of R&DApr 14Sale26.257,000183,734311,588Apr 16 04:19 PM
Cole G BradleyCOOApr 08Option Exercise2.883,0008,64025,226Apr 10 04:20 PM
Cole G BradleyCOOApr 08Sale27.003,00081,00022,226Apr 10 04:20 PM
Shak StevenEVP of R&DMar 14Option Exercise2.887,00020,160318,588Mar 18 05:39 PM
Shak StevenEVP of R&DMar 14Sale28.367,000198,493311,588Mar 18 05:39 PM
Cole G BradleyCOOMar 10Option Exercise2.883,0008,64025,226Mar 12 04:59 PM
Cole G BradleyCOOMar 10Sale27.763,00083,29022,226Mar 12 04:59 PM
HIBBS KATHY LSVP & General CounselFeb 18Sale27.881,31236,58415,787Feb 19 07:16 PM
Shak StevenEVP of R&DFeb 14Option Exercise2.887,00020,160320,643Feb 19 07:11 PM
Shak StevenEVP of R&DFeb 14Sale27.387,000191,630313,643Feb 19 07:11 PM
Cole G BradleyCOOFeb 10Option Exercise2.883,0008,64027,789Feb 12 04:51 PM
Cole G BradleyCOOFeb 10Sale27.003,00081,00024,789Feb 12 04:51 PM
Shak StevenEVP of R&DJan 15Option Exercise2.887,00020,160315,283Jan 17 01:39 PM
Shak StevenEVP of R&DJan 15Sale31.517,000220,601308,283Jan 17 01:39 PM
Popovits Kimberly JPresident and CEOJan 13Option Exercise9.392,50023,47529,366Jan 15 10:26 AM
Popovits Kimberly JPresident and CEOJan 13Sale30.002,50075,00026,866Jan 15 10:26 AM
Shak StevenEVP of R&D & CMODec 17Option Exercise2.887,00020,160315,283Dec 18 01:45 PM
Shak StevenEVP of R&D & CMODec 17Sale29.247,000204,671308,283Dec 18 01:45 PM
Shak StevenEVP of R&D & CMODec 16Option Exercise2.887,00020,160315,283Dec 18 01:45 PM
Shak StevenEVP of R&D & CMODec 16Sale29.917,000209,350308,283Dec 18 01:45 PM
Popovits Kimberly JPresident and CEODec 12Option Exercise9.392,50023,47529,366Dec 16 02:34 PM
Popovits Kimberly JPresident and CEODec 12Sale30.682,50076,70526,866Dec 16 02:34 PM
Schorno Dean LCFODec 09Option Exercise17.233,00051,69024,557Dec 10 04:40 PM
Schorno Dean LCFODec 09Sale33.253,00099,76121,557Dec 10 04:40 PM
LIVINGSTON RANDALL SDirectorDec 02Option Exercise10.731,00010,7307,149Dec 04 05:52 PM
LIVINGSTON RANDALL SDirectorDec 02Sale34.921,00034,9206,149Dec 04 05:52 PM
Popovits Kimberly JPresident and CEONov 13Option Exercise9.392,50023,47529,366Nov 14 05:59 PM
Popovits Kimberly JPresident and CEONov 13Sale35.002,50087,50026,866Nov 14 05:59 PM
Popovits Kimberly JPresident and CEONov 12Option Exercise9.392,50023,47529,366Nov 14 05:59 PM
Popovits Kimberly JPresident and CEONov 12Sale34.172,50085,42326,866Nov 14 05:59 PM
Schorno Dean LCFONov 08Option Exercise17.333,00051,99024,436Nov 13 07:45 PM
Schorno Dean LCFONov 08Sale33.363,000100,09021,436Nov 13 07:45 PM
Cole G BradleyCOONov 06Option Exercise1.332,8683,81421,003Nov 08 08:37 PM
Cole G BradleyCOONov 06Sale31.382,86889,98718,135Nov 08 08:37 PM
Shak StevenEVP of R&D & CMOOct 15Sale29.675,000148,341308,283Oct 17 05:05 PM
Popovits Kimberly JPresident and CEOOct 10Option Exercise4.792,50011,97829,366Oct 15 06:23 PM
Popovits Kimberly JPresident and CEOOct 10Sale30.002,50075,00026,866Oct 15 06:23 PM
Cole G BradleyCOOOct 09Option Exercise1.332,5003,32520,635Oct 11 04:50 PM
Cole G BradleyCOOOct 09Sale29.952,50074,88518,135Oct 11 04:50 PM
Shak StevenEVP of R&D & CMOSep 18Sale33.735,000168,629313,283Sep 20 05:38 PM
Popovits Kimberly JPresident and CEOSep 12Option Exercise2.882,5007,20029,366Sep 16 05:05 PM
Popovits Kimberly JPresident and CEOSep 12Sale34.312,50085,78726,866Sep 16 05:05 PM
Cole G BradleyCOOSep 09Option Exercise1.332,5003,32521,635Sep 11 04:05 PM
Cole G BradleyCOOSep 09Sale32.532,50081,32919,135Sep 11 04:05 PM
Schorno Dean LCFOSep 06Option Exercise17.294,00069,17824,486Sep 10 08:20 PM
Schorno Dean LCFOSep 06Sale32.904,000131,60021,436Sep 10 08:20 PM
LIVINGSTON RANDALL SDirectorSep 03Option Exercise10.731,00010,7307,149Sep 04 05:51 PM
LIVINGSTON RANDALL SDirectorSep 03Sale31.491,00031,4926,149Sep 04 05:51 PM
Shak StevenEVP of R&D & CMOAug 14Sale32.985,000164,906318,283Aug 16 07:24 PM
Popovits Kimberly JPresident and CEOAug 12Option Exercise2.882,5007,20029,366Aug 14 05:29 PM
Popovits Kimberly JPresident and CEOAug 12Sale33.032,50082,57326,866Aug 14 05:29 PM
Schorno Dean LCFOAug 09Option Exercise17.184,00068,72025,436Aug 12 08:48 PM
Schorno Dean LCFOAug 09Sale33.154,000132,58121,436Aug 12 08:48 PM
Cole G BradleyCOOAug 07Option Exercise1.332,5003,32521,635Aug 09 05:16 PM
Cole G BradleyCOOAug 07Sale33.662,50084,14019,135Aug 09 05:16 PM
Shak StevenEVP of R&D & CMOJul 23Sale35.335,000176,670318,283Jul 26 02:05 PM
Popovits Kimberly JPresident and CEOJul 12Option Exercise2.882,1006,04819,966Jul 15 07:57 PM
Popovits Kimberly JPresident and CEOJul 12Sale35.002,10073,50017,866Jul 15 07:57 PM
Popovits Kimberly JPresident and CEOJul 11Option Exercise2.882,9008,35220,766Jul 15 07:57 PM
Popovits Kimberly JPresident and CEOJul 11Sale34.322,90099,52817,866Jul 15 07:57 PM
Schorno Dean LCFOJul 09Option Exercise17.334,00069,32021,836Jul 10 07:47 PM
Schorno Dean LCFOJul 09Sale33.814,000135,23717,836Jul 10 07:47 PM
Cole G BradleyCOOJul 08Option Exercise1.332,5003,32515,635Jul 10 07:45 PM
Cole G BradleyCOOJul 08Sale33.332,50083,32713,135Jul 10 07:45 PM
Shak StevenEVP of R&D & CMOJun 18Sale33.525,000167,605323,283Jun 19 05:32 PM
Popovits Kimberly JPresident and CEOJun 12Option Exercise2.885,00014,40020,366Jun 14 04:39 PM
Popovits Kimberly JPresident and CEOJun 12Sale35.685,000178,40017,866Jun 14 04:39 PM
Schorno Dean LCFOJun 10Option Exercise17.334,00069,32021,836Jun 12 08:28 PM
Schorno Dean LCFOJun 10Sale35.884,000143,52517,836Jun 12 08:28 PM
Cole G BradleyCOOJun 05Option Exercise1.332,5003,32515,635Jun 07 05:34 PM
BAKER FELIXDirectorJun 05Buy35.82217,7737,799,54011,241,654Jun 05 05:23 PM
Cole G BradleyCOOJun 05Sale36.472,50091,17213,135Jun 07 05:34 PM
BAKER FELIXDirectorJun 04Buy36.62163,6595,993,19311,051,768Jun 05 05:23 PM
LIVINGSTON RANDALL SDirectorJun 03Option Exercise10.731,00010,7307,149Jun 04 07:03 PM
BAKER FELIXDirectorJun 03Buy36.69128,3414,708,43310,909,066Jun 03 05:40 PM
LIVINGSTON RANDALL SDirectorJun 03Sale36.401,00036,4006,149Jun 04 07:03 PM
BAKER FELIXDirectorMay 31Buy36.7551,2421,883,25610,797,159Jun 03 05:40 PM
BAKER FELIXDirectorMay 29Buy36.8247,0001,730,61510,752,532May 29 06:06 PM
BAKER FELIXDirectorMay 28Buy36.9374,2662,742,93310,711,599May 29 06:06 PM
BAKER FELIXDirectorMay 24Buy36.9362,5172,308,90910,646,920May 24 05:04 PM
BAKER FELIXDirectorMay 23Buy36.9116,900623,79910,592,521May 24 05:04 PM
HIBBS KATHY LSVP & General CounselMay 22Option Exercise21.071,00021,0708,087May 23 05:24 PM
HIBBS KATHY LSVP & General CounselMay 22Sale37.481,00037,4807,087May 23 05:24 PM
Shak StevenEVP of R&D & CMOMay 21Sale37.195,000185,957327,380May 22 07:54 PM
BAKER FELIXDirectorMay 16Buy36.5419,306705,42610,577,816May 16 06:03 PM
LIVINGSTON RANDALL SDirectorMay 15Option Exercise1.331,3371,7747,486May 17 05:33 PM
BAKER FELIXDirectorMay 15Buy36.4152,1331,898,36110,561,048May 16 06:03 PM
LIVINGSTON RANDALL SDirectorMay 15Sale35.831,33747,9046,149May 17 05:33 PM
BAKER FELIXDirectorMay 14Buy35.5327,184965,89910,515,769May 14 06:40 PM
HIBBS KATHY LSVP & General CounselMay 13Option Exercise21.071,25026,3388,337May 15 06:10 PM
Popovits Kimberly JPresident and CEOMay 13Option Exercise2.885,00014,40019,463May 15 06:08 PM
BAKER FELIXDirectorMay 13Buy34.19213,2427,291,16610,492,159May 14 06:40 PM
Popovits Kimberly JPresident and CEOMay 13Sale34.705,000173,50616,963May 15 06:08 PM
HIBBS KATHY LSVP & General CounselMay 13Sale34.421,25043,0317,087May 15 06:10 PM
Schorno Dean LCFOMay 09Option Exercise17.184,00068,72021,092May 13 05:33 PM
Schorno Dean LCFOMay 09Sale36.024,000144,08817,092May 13 05:33 PM
Cole G BradleyCOOMay 08Option Exercise1.332,5003,32515,040May 09 03:16 PM
Cole G BradleyCOOMay 08Sale35.992,50089,96412,540May 09 03:16 PM